Cargando…

The albumin-exendin-4 recombinant protein E2HSA improves glycemic control and β-cell function in spontaneous diabetic KKAy mice

BACKGROUND: E2HSA is a genetic fusion protein that consists of two tandem exendin-4 molecules that are covalently bonded to recombinant human serum albumin via a peptide linker. Previous studies have demonstrated that E2HSA significantly decreased blood glucose levels, improved β-cell function and p...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Caina, Hou, Shaocong, Liu, Shuainan, Huan, Yi, Sun, Sujuan, Liu, Quan, Shen, Zhufang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5477380/
https://www.ncbi.nlm.nih.gov/pubmed/28629388
http://dx.doi.org/10.1186/s40360-017-0143-8
_version_ 1783244780131581952
author Li, Caina
Hou, Shaocong
Liu, Shuainan
Huan, Yi
Sun, Sujuan
Liu, Quan
Shen, Zhufang
author_facet Li, Caina
Hou, Shaocong
Liu, Shuainan
Huan, Yi
Sun, Sujuan
Liu, Quan
Shen, Zhufang
author_sort Li, Caina
collection PubMed
description BACKGROUND: E2HSA is a genetic fusion protein that consists of two tandem exendin-4 molecules that are covalently bonded to recombinant human serum albumin via a peptide linker. Previous studies have demonstrated that E2HSA significantly decreased blood glucose levels, improved β-cell function and promoted β-cell proliferation in diabetic db/dB mice. This study aimed to evaluate the benefits of E2HSA on glucose and lipid metabolism in a spontaneous diabetes animal model, KKAy mice. METHODS: E2HSA was acutely administered at doses of 1, 3 and 9 mg/kg by subcutaneous injection in diabetic KKAy mice with exendin-4 (2 μg/kg) as a positive reference, and then the non-fasting blood glucose and food intake levels were dynamically monitored. In addition, different doses of E2HSA were injected once daily, as well as with exendin-4 twice daily, for 7 weeks to evaluate the effect on glucose and lipid metabolism, as well as the body weight, food and water intake. RESULTS: Single injection of E2HSA decreased non-fasting blood glucose and food intake levels in a dose-dependent manner for 4 days and 2 days, respectively. Repeated injections with E2HSA significantly decreased variations in blood glucose levels with a reduction of HbA1c levels by 1.6% at a 9 mg/kg dose, simultaneously increased fasting blood insulin levels, inhibited fasting blood glucagon levels, improved the impaired oral glucose tolerance and enhanced glucose infusion rate, which is the gold standard for evaluating β-cell function. Moreover, repeated injections with E2HSA also ameliorated the dyslipidemia and reduced body weight, food and water intake in diabetic KKAy mice. CONCLUSIONS: E2HSA significantly reduced blood glucose levels over a prolonged duration, enhanced β-cell function, and ameliorated dyslipidemia and obesity in diabetic KKAy mice. Thus, E2HSA may be a new candidate for the treatment of type 2 diabetes. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s40360-017-0143-8) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5477380
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-54773802017-06-23 The albumin-exendin-4 recombinant protein E2HSA improves glycemic control and β-cell function in spontaneous diabetic KKAy mice Li, Caina Hou, Shaocong Liu, Shuainan Huan, Yi Sun, Sujuan Liu, Quan Shen, Zhufang BMC Pharmacol Toxicol Research Article BACKGROUND: E2HSA is a genetic fusion protein that consists of two tandem exendin-4 molecules that are covalently bonded to recombinant human serum albumin via a peptide linker. Previous studies have demonstrated that E2HSA significantly decreased blood glucose levels, improved β-cell function and promoted β-cell proliferation in diabetic db/dB mice. This study aimed to evaluate the benefits of E2HSA on glucose and lipid metabolism in a spontaneous diabetes animal model, KKAy mice. METHODS: E2HSA was acutely administered at doses of 1, 3 and 9 mg/kg by subcutaneous injection in diabetic KKAy mice with exendin-4 (2 μg/kg) as a positive reference, and then the non-fasting blood glucose and food intake levels were dynamically monitored. In addition, different doses of E2HSA were injected once daily, as well as with exendin-4 twice daily, for 7 weeks to evaluate the effect on glucose and lipid metabolism, as well as the body weight, food and water intake. RESULTS: Single injection of E2HSA decreased non-fasting blood glucose and food intake levels in a dose-dependent manner for 4 days and 2 days, respectively. Repeated injections with E2HSA significantly decreased variations in blood glucose levels with a reduction of HbA1c levels by 1.6% at a 9 mg/kg dose, simultaneously increased fasting blood insulin levels, inhibited fasting blood glucagon levels, improved the impaired oral glucose tolerance and enhanced glucose infusion rate, which is the gold standard for evaluating β-cell function. Moreover, repeated injections with E2HSA also ameliorated the dyslipidemia and reduced body weight, food and water intake in diabetic KKAy mice. CONCLUSIONS: E2HSA significantly reduced blood glucose levels over a prolonged duration, enhanced β-cell function, and ameliorated dyslipidemia and obesity in diabetic KKAy mice. Thus, E2HSA may be a new candidate for the treatment of type 2 diabetes. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s40360-017-0143-8) contains supplementary material, which is available to authorized users. BioMed Central 2017-06-19 /pmc/articles/PMC5477380/ /pubmed/28629388 http://dx.doi.org/10.1186/s40360-017-0143-8 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Li, Caina
Hou, Shaocong
Liu, Shuainan
Huan, Yi
Sun, Sujuan
Liu, Quan
Shen, Zhufang
The albumin-exendin-4 recombinant protein E2HSA improves glycemic control and β-cell function in spontaneous diabetic KKAy mice
title The albumin-exendin-4 recombinant protein E2HSA improves glycemic control and β-cell function in spontaneous diabetic KKAy mice
title_full The albumin-exendin-4 recombinant protein E2HSA improves glycemic control and β-cell function in spontaneous diabetic KKAy mice
title_fullStr The albumin-exendin-4 recombinant protein E2HSA improves glycemic control and β-cell function in spontaneous diabetic KKAy mice
title_full_unstemmed The albumin-exendin-4 recombinant protein E2HSA improves glycemic control and β-cell function in spontaneous diabetic KKAy mice
title_short The albumin-exendin-4 recombinant protein E2HSA improves glycemic control and β-cell function in spontaneous diabetic KKAy mice
title_sort albumin-exendin-4 recombinant protein e2hsa improves glycemic control and β-cell function in spontaneous diabetic kkay mice
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5477380/
https://www.ncbi.nlm.nih.gov/pubmed/28629388
http://dx.doi.org/10.1186/s40360-017-0143-8
work_keys_str_mv AT licaina thealbuminexendin4recombinantproteine2hsaimprovesglycemiccontrolandbcellfunctioninspontaneousdiabetickkaymice
AT houshaocong thealbuminexendin4recombinantproteine2hsaimprovesglycemiccontrolandbcellfunctioninspontaneousdiabetickkaymice
AT liushuainan thealbuminexendin4recombinantproteine2hsaimprovesglycemiccontrolandbcellfunctioninspontaneousdiabetickkaymice
AT huanyi thealbuminexendin4recombinantproteine2hsaimprovesglycemiccontrolandbcellfunctioninspontaneousdiabetickkaymice
AT sunsujuan thealbuminexendin4recombinantproteine2hsaimprovesglycemiccontrolandbcellfunctioninspontaneousdiabetickkaymice
AT liuquan thealbuminexendin4recombinantproteine2hsaimprovesglycemiccontrolandbcellfunctioninspontaneousdiabetickkaymice
AT shenzhufang thealbuminexendin4recombinantproteine2hsaimprovesglycemiccontrolandbcellfunctioninspontaneousdiabetickkaymice
AT licaina albuminexendin4recombinantproteine2hsaimprovesglycemiccontrolandbcellfunctioninspontaneousdiabetickkaymice
AT houshaocong albuminexendin4recombinantproteine2hsaimprovesglycemiccontrolandbcellfunctioninspontaneousdiabetickkaymice
AT liushuainan albuminexendin4recombinantproteine2hsaimprovesglycemiccontrolandbcellfunctioninspontaneousdiabetickkaymice
AT huanyi albuminexendin4recombinantproteine2hsaimprovesglycemiccontrolandbcellfunctioninspontaneousdiabetickkaymice
AT sunsujuan albuminexendin4recombinantproteine2hsaimprovesglycemiccontrolandbcellfunctioninspontaneousdiabetickkaymice
AT liuquan albuminexendin4recombinantproteine2hsaimprovesglycemiccontrolandbcellfunctioninspontaneousdiabetickkaymice
AT shenzhufang albuminexendin4recombinantproteine2hsaimprovesglycemiccontrolandbcellfunctioninspontaneousdiabetickkaymice